AbbVie
ABBV
3,169 hedge funds and large institutions have $255B invested in AbbVie in 2022 Q4 according to their latest regulatory filings, with 365 funds opening new positions, 1,192 increasing their positions, 1,262 reducing their positions, and 101 closing their positions.
261% more first-time investments, than exits
New positions opened: 365 | Existing positions closed: 101
54% more capital invested
Capital invested by funds: $166B → $255B (+$89.1B)
25% more funds holding in top 10
Funds holding in top 10: 278 → 348 (+70)
7% more funds holding
Funds holding: 2,969 → 3,169 (+200)
0.19% less ownership
Funds ownership: 70.04% → 69.85% (-0.19%)
4% less call options, than puts
Call options by funds: $2.99B | Put options by funds: $3.13B
6% less repeat investments, than reductions
Existing positions increased: 1,192 | Existing positions reduced: 1,262
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$881M |
| 2 |
Morgan Stanley
New York
|
+$734M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$503M |
| 4 |
JP Morgan Chase
New York
|
+$373M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$352M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$2.59B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$628M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$432M |
| 4 |
CIAS
CFS Investment Advisory Services
Totowa,
New Jersey
|
-$378M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$186M |
ABBV Hedge Fund Activity: Q4 2022 in Review
3,169 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2022, worth a combined $255B — up 54% from $166B a quarter earlier.
Buyers outnumbered sellers: 365 funds opened new ABBV positions and 101 closed out — a net gain of 264 holders — while 1,192 added to existing stakes and 1,262 trimmed.
The largest buyer was BlackRock, adding an estimated $881M. The largest seller was Janus Henderson Group, cutting an estimated $2.59B.
- 3,169 institutional investors held AbbVie (ABBV) as of Q4 2022, up from 2,969 in Q3 2022.
- Funds reported $255B of AbbVie stock for Q4 2022, up 54% quarter-over-quarter.
- 365 funds opened new AbbVie positions in Q4 2022 and 101 closed out, a net change of +264 holders.
- The largest AbbVie buyer in Q4 2022 was BlackRock, an estimated $881M added.
- The largest AbbVie seller in Q4 2022 was Janus Henderson Group, an estimated $2.59B sold.
Based on aggregated 13F filings for Q4 2022.